This study is for adults with Chronic Kidney Disease (CKD) and high protein levels in their urine. CKD means the kidneys aren't working as well as they should. The study compares two treatments: one with both zibotentan and dapagliflozin, and the other with dapagliflozin alone. Dapagliflozin is a medicine often used for diabetes that helps the kidneys by removing extra sugar and salt from the body. Zibotentan helps blood vessels to relax and widen.

To join, you need to be 18 or older and have CKD with a specific level of kidney function and protein in your urine. Women must not be pregnant or planning to become pregnant. You also need to be on a stable dose of certain other kidney medicines. You cannot participate if you have certain heart conditions, very high or low blood pressure, or recent serious illnesses.

• The study is "double-blinded," meaning neither you nor the doctors will know which treatment you are getting to ensure fairness.
• You will need to come in for regular check-ups to ensure safety and see how well the treatment is working.
• There may be some risks, and you should discuss with your doctor to see if it’s right for you.